TrialAmerican journal of clinical dermatology2025

Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.

M Peter Marinkovich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.